Skip to content

Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04744935
Enrollment
40
Registered
2021-02-09
Start date
2021-01-13
Completion date
2027-02-17
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal Cell Carcinoma, Nodular Basal Cell Carcinoma, Superficial Basal Cell Carcinoma

Keywords

Basal cell carcinoma, Superficial basal cell carcinoma, Nodular basal cell carcinoma, Optical coherence tomography, OCT, Laser

Brief summary

Optical coherence tomography guided laser treatment of basal cell carcinoma

Detailed description

The purpose of this pilot study is to examine the treatment basal cell carcinoma (BCC) with laser technology under the guidance of optical coherence tomography imaging (OCT). The laser modality that we plan to use is the long-pulse Nd:YAG 1064nm laser, which is a non-ablative laser already shown to effectively treat BCC. Laser treatment of BCC has limited precedent in the literature, but the addition of OCT has the opportunity to enhance outcomes by better targeting the treatment and permitting more precise monitoring of clearance. We propose to use OCT imaging to guide the laser treatment to achieve optimal efficacy with minimized side-effects.

Interventions

BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.

Sponsors

Christopher Zachary
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Ability to understand and carry out subject instructions or be represented by a legally authorized guardian or representative * Ages 18 and older * Seeks and is scheduled for treatment of a BCC previously confirmed with biopsy

Exclusion criteria

Any of the following will exclude participation in the study: * Inability to understand and/or carry out instructions * Patients with a BCC lesion that requires excision. This would include relatively large lesions (\>2.5 cm diameter), lesions that penetrate deep into the skin beyond the depth of the OCT image capture, high risk lesions as defined by the American Academy of Dermatology as recurrent and sclerosing subtype BCC, or metastases. * Patients with periocular BCCs which might expose the patient to risk of damage to eyes from the laser. * BCCs on legs due to their tendency towards poor wound healing. * Pregnancy * Patients unable to follow-up for the full 12 months.

Design outcomes

Primary

MeasureTime frameDescription
Complete histological clearance of BCC lesion1 yearThose whose lesion is not in a cosmetically sensitive area will undergo a skin biopsy for histological confirmation of OCT results.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORChristopher Zachary, MBBS FRCP

University of California, Irvine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026